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Mitogen activated protein kinases (MAPK) p38 and ERK have both been reported to bind 
endothelial nitric oxide synthase (eNOS) with submicromolar affinity via proposed interactions 
with a pentabasic non-canonical MAPK binding sequence in the autoinhibitory insertion of eNOS. 
The neuronal isoform, which lacks the pentabasic motif, did not bind either MAPK significantly. 
In the present study, the pentabasic motif was validated using predictive modeling programming, 
and eNOS phosphorylation by MAPKs (P38, ERK and JNK) was examined using in vitro kinase 
assays and immunoblotting. JNK phosphorylation at Ser114 contrasts with ERK, which 
phosphorylated Ser600, and p38, which phosphorylated both sites. Literature reports showed that 
JNK1/2 activation does not alter eNOS activity and prior work in our lab showed that ERK 
phosphorylation negativity affects NO output. This thesis presents in vitro results comparing the 
direct impact of each kinase on eNOS activity using the oxyhemoglobin (Oxy-Hb) assay. In 
HMEC-1 cells and in vitro it is observe that phosphorylation at these MAPK sites happens 
concurrently with activating sites (Ser1177), creating dually phosphorylated eNOS. These results 
underscore the importance of MAPK interactions with eNOS showing that each MAPK creates a 
unique phosphorylation pattern and NO production outcome. These findings strengthen the 
emerging paradigm of eNOS as a junction of multiple signaling pathways. 
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Chapter 1: Literature Review 
SIGNIFICANCE OF RESEARCH  
Cardiovascular Disease 
According to The Center for Disease Control and Prevention (CDC), approximately 90 
million people have known cardiovascular disease. Of these, 800,000 people have heart attacks 
and over 500,000 people die from heart disease every year (1, 2). One cardiovascular disease is 
atherosclerosis, the hardening and narrowing of arteries. Usually, atherosclerosis is asymptomatic. 
However, by the time the disease becomes symptomatic, the arteries have constricted to the point 
of creating a life-threatening situation.  
 
Type 2 Diabetes Mellitus 
In 2015, the American Diabetes Association (ADA) reported that more than 30 million 
Americans have been diagnosed with diabetes; this is approximately 9% of the population. The 
CDC states that Type-2 Diabetes Mellitus (T2DM) accounts for 90 to 95 percent of all diagnosed 
cases (3). T2DM results from the loss or dampened function of beta-cells to secrete enough insulin 
to maintain normal blood glucose levels. This results in cellular insulin resistance via 
hyperinsulinemia (increased insulin secretion due to hyperglycemia; increased blood glucose). 
People who are insulin resistant undergo phenotypic changes that result in glucose abnormalities 
such as impaired trafficking of glucose into peripheral tissue (4). Normally, glucose enters the 
blood-stream via the liver and digestive system; the pancreas secretes insulin which is then 
recruited to the insulin receptor; promoting glucose uptake into tissues (4).  
 
Link between Diseases  
Investigating both of these diseases has revealed many overlapping pathways between 
T2DM and cardiovascular disease. Our work is focused on a molecule implicated in both 
pathways, Nitric Oxide (NO). NO is a gaseous small molecule that signals and effects an array of 
physiological processes. Changes in NO production are involved in the progression of 
atherosclerosis (5–10). T2DM patients have also been shown to have decreased levels of detectable 
NO and are not able to secrete sufficient insulin in response to hyperglycemia and this contributes 
to the development of insulin resistance. While it is known that NO plays a role in the development 
of insulin resistance (11, 12), the capacity and the molecular mechanism in which NO regulates 
inulin resistance remain unknown. 
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THE DISCOVERY OF NITRIC-OXIDE AS A SIGNALING MOLECULE 
NO diffuses extracellularly, targets smooth muscles cells, blood platelets, and affects an 
array of physiological processes, including mitochondrial biosynthesis, neurotransmission, blood 
pressure regulation, smooth muscle relaxation, and immune function (13–17). In the late 1970s, 
NO was known as a common air pollutant formed through the burning of nitrogen and biologically 
thought to be another ligand that could activate guanylate cyclase. However, in the 1980s, NO was 
appreciated as a critical endogenous vasorelaxant molecule.  
The work of the Robert F. Furchgott, Louis J. Ignarro, and Ferid Murad labs changed our 
understanding of NO.  
Their work demonstrated that endothelial derived relaxation factor (EDRF) was in fact NO 
and that this gas could function as a signaling molecule in the cardiovascular system. Further work 
Figure 1: Pathways involved in the synthesis of nitric oxide and the downstream physiological 
effects of the gas.  
NO3 - nitrate, NO2 - nitrite, NOS - nitric-oxide synthase. NO signals a number of 
physiological responses such as angiogenesis, inflammation, and vasodilation leading to the 
regulation of blood pressure, muscular relaxation, and vascular remodeling. Lower NO 
production and increased NO inactivation are major factors that contribute to the increase of 
endothelial dysfunction –adopted from (83) 
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revealed that nitroglycerin and other vasodilatory molecules release NO, which enables relaxation 
of smooth muscle cells (18, 19). As a result of their work, it is now understood how an unstable 
molecule like NO with a biological half-life of 10 seconds functions as an important signaling 
molecule in the cardiovascular system. 
 
Nitric-Oxide Promotes Angiogenesis and Cell Migration     
Endothelium-derived NO was found to be necessary for the promotion of angiogenesis 
signaled by the release of vascular endothelial growth factor (VEGF) (20–22). However, NO-
mediated angiogenesis has not been fully elucidated. It is known that NO works to inhibit apoptosis 
and promotes endothelial cell survival and proliferation through the expression of VEGF (22). 
Furthermore, NO promotes endothelial migration through the stimulation of endothelial cell 
podokinesis, best defined as the scalar control of micromotion to vectorial movement (22–24). N-
nitro-L-arginine methyl ester (L-NAME) is a competitive inhibitor of NO synthesis and suppresses 
endothelial cell migration in human umbilical vascular endothelial cells (HUVEC) (23). Taken 
together, these findings show that endothelium-derived NO is important for endothelial cell 
survival, migrations, and angiogenesis.  
 
NITRIC-OXIDE SYNTHASES    
Nitric-Oxide Synthases (NOS) are a family of enzymes that catalyze the production of 
nitric-oxide (NO) from L-arginine; there are three main isoforms indicative of where they were 
discovered. NOS I (iNOS; inducible/immune nitric-oxide synthase), NOS II (nNOS; neuronal 
nitric-oxide synthase), and NOS III (eNOS; endothelial nitric-oxide synthase). All isoforms of 
NOS use L-arginine, molecular oxygen (O2), and nicotinamide-adenine-dinucleotide phosphate 
(NADPH) as co-substrates. All have a heme prosthetic group, and all use flavin adenine 
dinucleotide (FAD), flavin mononucleotide (FMN), and (6R-)5,6,7,8-tetrahydro-L-biopterin 
(BH4) as cofactors (25). NOS isoforms exist as homodimers and cannot produce NO unless 
dimerized (26, 27).  
In order for NOS to produce NO the guanidine nitrogen of L-arginine is hydrolyzed to an 
N-hydroxy-L-arginine (NOHA) intermediate; NOHA is further oxidized by NOS to form NO and 
L-citrulline (28). The balanced reaction for the production of NO is 2 L-arginine + 3 NADPH + 3 H+ + 
4 O2 ⇋ 2 citrulline + 2 NO + 4 H2O + 3 NADP+. Simply put eNOS consumes 1 mole of L-arginine, 1.5 
4 
moles of NADPH, and 2 moles of oxygen to produce NO. The catabolic reaction described can be 
altered through a number of mechanisms including direct protein interactions and post-
translational modifications. The binding of NADPH to NOS initiates the transfer of electrons 
through the flavin molecules to the heme complex and allows for heme to bind and activate 
molecular oxygen for NO production (Figure 2). However, without calmodulin (CaM) binding 
NOS is rendered inactive because the reductase domain cannot coordinate with the oxygenase 
domain (29, 30). CaM is a ubiquitously expressed small Ca2+ binding protein that enhances the 
rate of electron transfer from NADPH to the flavin molecules and ultimately the heme complex 
and was the first protein shown to interact with NOS (28). Furthermore, CaM functions as a 
coordinator of both the oxygenase and reductase domain, for all three NOSs.  
 
Interdomain Electron Transfer, Dimerization, and eNOS Catalysis   
NOSs evolutionarily have similar protein structures characterized by an N-terminal 
catalytic heme-containing oxygenase domain (NOSoxy) and a C-terminal flavin-containing 
reductase domain (NOSred). NOSoxy contains binding sites for a zinc tetrathiolate and heme 
center. (6R)-5,6,7,8-tetrahydrobiopterin (BH4) and L-arginine are linked by a CaM-recognition 
site to NOSred which contains binding sites for flavin adenine dinucleotide (FAD), flavin 
Figure 2: Schematic overview of NOS structure  
The oxygenase domain (N-terminal) and a reductase domain (C-terminal) separated by a 
calmodulin binding domain. The reductase domain binds NADPH and contains binding sites 
for FMN and FAD. The oxygenase domain contains binding sites for BH4 and heme and also 
binds L-arginine. Note: Electrons are transferred from the NADPH donor via FMN and FAD 
through the reductase domain to the oxygenase domain of the adjacent monomer (not shown).   
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mononucleotide (FMN), and NADPH. NOSoxy and NOSred are connected by a CaM binding 
linker sequence that catalyzes the flow of electrons from the NADPH donor through NOSoxy to 
the heme center, where molecular oxygen is bound and activated. All the isoforms have this linker, 
but iNOS is unique in that CaM binding is Ca2+ independent, while it is a Ca2+ dependent event 
for eNOS and nNOS. Additionally, NOS is only able to produce NO as a homodimer (fully 
coupled) interfacing through the heme domains. Under this condition, NO production requires 1.5 
NADPH molecules per NO molecule; any deviation from this results in uncoupled eNOS and the 
production of alternate reactive oxygen 
species (ROS) such as superoxide. Another 
difference that eNOS and nNOS have from 
iNOS is the insertion of an auto-inhibitory 
loop (AI insertion). The AI insertion is a 
flexible 37 amino acid sequence that is often 
embedded within the structure (not exposed to 
the protein surface). The AI insertion contains 
a conserved helical region that essentially 
stabilizes eNOS/nNOS and prevents 
conformational changes necessary for the 
catalytic cycle and will be discussed further 
within the thesis.  
The dimer interface involves a large 
portion of the NOSoxy domain; this interface 
involves the binding site for BH4 and structures the “active site” pocket for heme and L-arginine 
incorporation. Furthermore, eNOS contains an N-terminal beta-hairpin hook that stabilizes 
dimerization (61aa-106aa in bovine eNOS) by exchanging “switching” between the two 
monomers. The “switching” mechanism is thought to be only for stabilization purposes, as 
heterodimers of both full-length NOS and hook-defective mutants were active in almost all cases 
(27, 31).  The N-terminal hook region primarily interacts with its own subunit in the unswapped 
conformation and crosses to associate with the opposite subunit in the swapped conformation (27).  
Catalysis of all three NOS isoforms depend on the cofactor BH4; binding of BH4 causes 
the heme center to shift to its high-spin state (maximum peak at 400nm (32)). BH4 is a key 
Figure 3: Sequence Alignments of the Zinc-
Binding Motif 
Conservation among NOS cysteines that 
coordinate the zinc ligand. Within the Cys-
(X)4-Cys motif the (X) 4 appears to prefer 
hydroxylated (Ser and Thr) and charged (Arg, 
His, and Lys) residues. Modified from (37). 
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regulator of NOS, functioning as an allosteric regulator for L-arginine binding (31, 33, 34). BH4 
binding causes a conformational change in NOS that increases eNOS affinity for arginine-based 
ligand binding (35, 36). BH4 is further stabilized through zinc coordination with Cys96 and Cys101. 
Evolutionary, NOS contains this Cys-(X)4-Cys motif (Figure 3) allowing zinc to form a zinc-
tetrathiolate between the two monomers (27, 37, 38). The (Xs) are usually hydroxylated and 
charged residues. The zinc ligand is critical for eNOS dimerization in vivo; if zinc were missing 
the reducing conditions of the cytosol would prevent the cysteine sulfhydryl coordination (37). In 
other words, weak zinc coordination results in eNOS deterioration and subsequently less NO 
synthesis.  
 
ENDOTHELIAL NITRIC-OXIDE SYNTHASE 
Endothelial Nitric-Oxide Synthase functions as a major vasoprotective protein due in large 
part because it is expressed at high levels in vascular endothelial cells. Interestingly, eNOS has a 
number of unique means of regulation. For example, eNOS is co-translated with a myristoyl group 
covalently attached to the glycine residue in the first amino acid position (the met residue is cleaved 
off in the process of myristoylation (39). This allows eNOS to localize to specialized plasmamonal 
invaginations coined caveolae and stay in close proximity with other factors that negatively 
regulate its function (34). eNOS can also localize to other regions in the membrane that allow for 
positive regulation. Research suggests that myristoylation is a requirement of membrane 
localization and eNOS yields maximum activity at the membrane (40). Another study suggested 
that myristoylation targets eNOS to the Golgi complex (41), where eNOS is post-translationally 
modified by palmitoylation at cysteine residues 15 and 25 to allow for the tighter anchorage at the 
Golgi membrane (26). Myristoylation is required before palmitoylation can occur; through 
palmitoylation modifications are reversible. Studies suggest that palmitoylation may help stabilize 
eNOS and is required for localization (42). eNOS localized to caveolae generally associates with 
caveolin 1 (43).  
 
KINASE REGULATION OF ENOS 
eNOS Regulation by Phosphorylation    
eNOS plays a critical role in maintaining vascular integrity via the enzymatic generation 
of NO. The enzyme is regulated by phosphorylation at tyrosine (Tyr), threonine (Thr), and serine 
(Ser) residues (Table 1). One study shows that hyperphosphorylation in response to agonists and 
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shear stress promotes activating 
and inhibitory alterations in NO 
generation (44). Of these sites, 
known activation sites include 
Ser615, Ser633, and Ser1177. Known 
inhibitory sites include Tyr83, 
Ser114, Ser600, Thr495, and Tyr657 
(45, 46). A number of residues are 
targeted by the phosphatidylinositol-3 kinase (PI-3K) pathway; which activates the downstream 
kinase AKT, which in turn phosphorylates eNOS. Increased intracellular calcium levels activate 
CaM and sequentially CaM kinase II activation and Ser1177 phosphorylation. Studies show that 
phosphorylation of Ser1177 renders the enzyme more responsive to much lower levels of calcium 
(47). Furthermore, eNOS phosphorylation by mitogen-activated-protein kinase (MAPK) dampens 
NO generation and causes endothelial dysfunctional such as T2DM (48).   
 
 
Mitogen-Activated Protein Kinases 
Mitogen-activated Protein Kinases or MAP kinases are serine/threonine kinases that 
transmit extracellular signals into a wide range of intracellular responses. Highly conserved among 
Eukaryotes, MAPKs participate in the most ancient signal transduction pathways and are widely 
used throughout evolution in many physiological processes (49). Activation of MAP kinases cause 
phosphorylation of a variety of intracellular targets including transcription factors, transcriptional 
adaptor proteins, membrane and cytoplasmic substrates, and other protein kinases and will 
ultimately lead to physiological functions including growth, cell division, apoptosis, development, 
metabolism, proliferation, diabetes, cancer, angiogenesis, and others.  
Conventional MAPKs follows a classical three-tiered kinase cascade; MAPKK kinase 
(MAPKKK), to MAPK kinase (MAPKK), to MAP kinase. Currently there are fourteen 
MAPKKKs, (Raf-1, A-Raf, B-Raf, Mos, TAK1, MUK, SPRK, MST, MEKK 1-4, Tpl-2, and ASK) 
seven MAKKs, (MEK1&2, MKK3-7) and 12 MAP Kinase (c-JUN amino (N)-terminal kinases 
(JNK1/2/3), p38 (), and ERK1-5) (Figure 4). This work focuses on how MAP Kinases 
(P38, ERK, and JNK) regulate eNOS.  






Tyrosine 87 Increases  SRC 
Serine 114 Decreases? JNK/P38 
Threonine 495 Decreases PKC 
Serine 600 Decreases? ERK/P38 
Serine 615 Increases  PKA/AKT 
Serine 633 Increases  PKA 
Serine 1177 Increases  PKA/AKT/CaMKII 
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 Extracellular Signal Regulated Protein Kinase  
Extracellular-signal-regulated kinase (ERK) is stimulated by growth factors and mitogens. 
This promotes a downstream activation cascade and leads to the phosphorylation and activation of 
ERK to carry out physiological processes such as cellular growth, proliferation, and differentiation. 
Our lab determined that ERK phosphorylates eNOS at Ser600 and hypothesized that it caused a 
conformational change in eNOS structure, which resulted in decreased NO generation (46). 
Furthermore, mass spectrometry identified three sites of ERK phosphorylation in vitro: Thr46, 
Ser58, and Ser600.   
ERK binds with high affinity and phosphorylates endothelial nitric-oxide synthase (eNOS) 
(46, 50). However, controversy exists regarding the modulation of eNOS through the MAP kinase 
pathway. Some studies report that ERK enhances NO synthesis through increased eNOS 
expression (51, 52) while others report inhibition (34, 46) of eNOS activity through 
phosphorylation. Most of the confusion stems from reports about which sites on eNOS are 
Figure 4: Schematic overview of MAPK pathways  
MAP Kinases shuttle between the cytoplasm and the nucleus, catalyze the phosphorylation of 
dozens of cytosolic proteins and numerous nuclear transcription factors impacting many 
cellular processes. See text for details -adapted and modified from (84) . 
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phosphorylated by ERK (53). Our lab and other groups have shown that ERK interacts with eNOS 
(46, 50, 53); i.e. in cells ERK is released from eNOS in response to bradykinin stimulation and 
later re-complexes (53).  
 
c-Jun N-terminal kinase  
c-Jun N-terminal kinase (JNK) is stimulated by stressors such as hyper-osmosis, oxidative 
stress, and inflammatory cytokines (see figure 4). These stimuli promote the activation of 
downstream kinases, ultimately leading to the phosphorylation and activation of JNK. The JNK 
pathway is implicated in a number of physiological responses including cellular cycle arrest, 
apoptosis, inflammation, growth, and cellular differentiation. JNK was also shown to directly 
phosphorylate eNOS at Ser114 altering its activity (54). In this study, a dominant negative of 
JNK1/2 was introduced to BAEC cells. As expected, dn-JNK2 significantly increased basal NO; 
increasing confidence that JNK1/2 phosphorylates eNOS in vitro and in situ (54). Furthermore, 
JNK2 co-immunoprecipitated with eNOS from cell lysates and confocal microscopy reveals that 
JNK1/2 appears to be co-localized in the cytosol of BAEC cells (54). Overall, these results suggest 
that eNOS directly interacts with JNK1/2 and treatment with JNK inhibitor SP600125 increases 
basal NO generated in BAE cells.  
 
Protein Kinases AGC 
MALDI-TOF mass spectrometry data suggests protein kinase A (PKA) phosphorylates 
Ser615, Ser633 and Ser1177 while protein kinase B (AKT) phosphorylates only at Ser615 and Ser1177 
(55). However, our lab has shown (in vitro) that both kinases can phosphorylate all three activating 
sites. Cellular conditions such as sheer stress and serum induced activation of AKT have been 
shown to increase eNOS-induced synthesis of NO through phosphorylation at Ser1177 and Ser615 
respectively (26, 56). HUVEC exposed to shear stress for up to one hour resulted in the rapid (2-
fold increase) phosphorylation and subsequent activation of AKT.  
Further experimentation showed that phosphomimetic S1177D mutants results in 
significantly augmented eNOS enzymatic activity measured using the labeled L-citrulline assay 
(56). In contrast, overexpression of the eNOS phospho-null construct S1177A prevented AKT 
phosphorylation of eNOS at Ser1177 by sheer stress (56). Furthermore, it was thought that 
phosphorylation at Ser1177 would increase NO synthesis independently of Ca2+ stimulation. As 
expected, the results showed that stepwise decreases in CaCl2+ resulted in stepwise decreases in 
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wild-type eNOS activity. However, the phosphomimetic S1177D remained active despite 
alterations Ca2+ stimulation. Together these results show that shear stress-induced phosphorylation 
of eNOS by AKT enhances enzyme activity in a Ca2+ dependent manner (56).  
eNOS phosphorylation at Thr495 by PKC results in decreased calmodulin binding, 
decreased NO synthesis, and increased association with caveolin (57). These investigators 
incubated BH4 free eNOS with and without AKT or PKC. AKT significantly increased superoxide 
synthesis showing that phosphorylation at Ser615, Ser633, & Ser1177 also promotes activation of 
uncoupled eNOS. Conversely, PKC-mediated phosphorylation also inhibited superoxide synthesis 
via phosphorylation at Thr495 and shows that phosphorylation at Thr495 significantly inhibits eNOS 
activity.  
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Hypothesis and Specific Aims 
 
This research aimed to understand the regulation of eNOS that occurs through MAP Kinases, 
including protein-protein interactions and phosphorylation. 
 
 
The specific aims were: 
1. To develop a model of human eNOS reductase and measure the distances between kinase 
docking and phosphorylation sites. 
2. To determine whether MAP Kinases differentially phosphorylate eNOS and whether this 
alters NO synthesis rate.  
3. To determine the physiological relevance of eNOS phosphorylation at Ser600. 
 
  
Figure 5: Graphical Hypothesis   
PKA phosphorylates eNOS at Ser1177 increasing eNOS activity while we propose MAP 
Kinases P38, JNK, and ERK phosphorylate eNOS at Ser600 and/or Ser114 and decreases eNOS 
activity. However, we question how phosphorylation at Ser1177 congruently with 
phosphorylation at Ser600/Ser114 affects eNOS activity.  
12 
Chapter 2: MAP Kinases Recognition Sequences in Human eNOS 
    
INTRODUCTION 
Our lab has shown that both P38 and ERK2 bind to eNOS with high affinity whereas ERK 
weakly binds nNOS and P38 does not bind nNOS (50). This work was followed by a closer 
examination of how ERK binds, phosphorylates, and alters eNOS activity (46). ERK-
phosphorylated eNOS was sent for mass spectroscopy; that data identified three novel 
phosphorylation sites (46), of which the Ser600 position was identified as an ideal regulatory site. 
Ser600 falls within the eNOS autoinhibitory (AI) insertion. This region is homologous in eNOS and 
nNOS however, only eNOS has a conserved pentabasic motif (627Arg-Arg-Lys-Arg-Lys631) within 
the AI insertion. The pentabasic motif is homologous to known MAP kinase binding sequences, 
so the lab hypothesized that this region could be responsible for the strong binding of MAP Kinases 
to eNOS and not nNOS. Our lab proposed that ERK binds the pentabasic motif and phosphorylates 
eNOS at Ser600. Though not fully tested, it was interpreted through experimentation using FMN 
fluorescence lifetime imaging that phosphorylation at Ser600 by ERK was likely disrupting the flow 
of electrons through the eNOS reductase domain and negatively impacting NO production.  
Around the same time, another group suggested that the MAP Kinase JNK recognizes 
another motif conserved in eNOS within the oxygenase domain (98P-Arg-Arg-CLGS-Leu-Val-
Leu-P108; PRRC motif) (54). Looking closely at the proposed PRRC motif it is also not well 
conserved in nNOS and that led us to hypothesize that the MAP Kinases may differentially bind 
eNOS. Together with phosphorylation data, it is hypothesized that ERK binds the pentabasic motif 
preferentially and phosphorylates eNOS at Ser600. JNK is hypothesized to bind at the PRRC motif 
and phosphorylate eNOS at Ser114, and P38 is hypothesized to bind and phosphorylate both sites. 
Therefore, it was decided that utilizing bioinformatics and structural modeling techniques were 
best to probe these hypotheses.  
A literature search revealed the existence of a crystal structure of Arrestin 2 and MEK1 has 
been shown to interact with Arrestin 2 (58). This served as a positive control for the distance 
between the kinase docking site and the known phosphorylation site. MEK1 binds Arrestin2 
at 26EFVE29 (58) which is visible in the crystal structure; however, MEK1 
phosphorylates Arrestin 2 at Ser412 which is not visible in the crystal.   
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Bioinformatics and Computational Programs  
There are currently no crystal structures of eNOS reductase domain. Therefore, designing 
a model is necessary to test if the pentabasic motif is within an appropriate distance that would 
allow MAP Kinases to mediated phosphorylation at nearby sites. UniProt (59), Jalview (60), 
PROMALS3D (61), I-Tasser (62–64), and PyMOL (65) were used to design a model. UniProt is 
a comprehensive protein database that pulls sequences from EMBL-Bank, GenBank, and DDBJ 
nucleotide sequence resources. Jalview is a free editing and visualization analysis program. 
PROMALS3D is a multiple sequence alignment (MSA) program that incorporates information 
from crystal structures to create structurally-informed secondary structures MSAs. I-Tasser is an 
online platform that generates quality predictive 3D models of protein structures. The servers 
retrieve structures of similar sequences from the PDB to use as a template(s) for modeling. 
Insertions in the query sequence are modeled ab initio. PyMOL is another visual analytic program, 
mainly for the visualization of micro and macromolecules and is heavily used in structural biology. 
The Py extends to the programing language Python.   
 
Objective and Hypothesis 
Our objective is to determine whether the distances between the putative MAP Kinases 
recognition sequences – pentabasic motif or PRRC motif –  and the respective phosphorylation 
sites on eNOS are realistic, by comparing them to the distances between MEK binding and 
phosphorylation sites in Arrestin2 (66).  
  
EXPERIMENTAL PROCEDURES     
Materials and Methods  
Identifying NOS Isoforms for Creating a Multiple Sequence Alignment     
Queries for various text strings – nitric oxide synthase endothelial, nitric oxide synthase 
neuronal, and nitric oxide synthase inducible – were submitted to the UniProt database. The query 
for nitric oxide synthase endothelial resulted in 163 peer-reviewed hits and was further filtered to 
select sequences from diverse species including plants (tulips) and vertebrate (mammals such as 
human, pigs, bovine and non-mammals such as fish, chickens, bats, and reptiles) and is shown in 
supplementary table 1. For example, one eNOS sequence was added to our list by clicking 
Eukaryota followed by Anthurium amnicola (tulip). The query search for nitric oxide synthase 
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neuronal resulted in 137 reviewed hits and was further filtered to include sequences from diverse 
species (mammals, plants, hydrozoans, and non-mammals) similar to the ones from the eNOS 
query. The same process was used for the query nitric oxide synthase inducible (114 reviewed 
hits) however, more fish were included for this selection as well as plants and vertebrates. Taken 
together a total of 39 hits were selected from our query of eNOS 30 from nNOS and 34 from iNOS 
queries and can be found in supplemental table 1. The selected NOS sequences were downloaded 
as individual FASTA files, loaded into Jalview  (60), and saved as a multi-FASTA file.    
    
Designing a Structurally Informed Multiple Sequence Alignment of NOS   
After a comprehensive literature search, crystal structures of rat nNOS reductase domain 
(1TLL (67)), rat nNOS FAD/NADP+ domain (1F20 69), and the human iNOS reductase and 
calmodulin complex (3HR4) were selected as crystal templates to include for structural 
information with PROMALS3D. The NOS sequences selected from the database search were 
submitted to the PROMALS3D webserver (61), specifying the three crystal structures use for 
structural information; all other settings were default. After three days PROMALS3D returned a 
structurally informed MSA which was visualized in Jalview (Figure 6) (60). This MSA and the 
crystal structures were used to inform the decision to use position 492aa as the beginning of the 
human eNOS (heNOS) reductase domain.     
 
 
Figure 6: NOS Multiple sequence alignment  
High quality NOS sequence alignment queried from diverse species. Residues are colored according to side 
chain characteristics. The red arrow indicates the amino acid where human eNOS was truncated. The green 
arrow depicts where crystal structure 1TLL 13 starts.  
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heNOS Model Design and Verification      
The reductase domain of heNOS was submitted to I-Tasser (62–64) with default settings. 
Five models were returned along with the associated confident scores (C-score). To verify that the 
model was conformationally correct 1TLL (67) was superimposed to the model using the align 
tool in PyMOL (65). The alignment of the model with the crystal structure agreed with the MSA, 
providing confidence in the model’s accuracy.    
    
 Determining Kinases Docking Sites to Phosphorylation Sites   
The crystal structure of the MEK/Arrestin complex (2WTR) (66), the crystal structure of 
the oxidase domain of bovine eNOS (1NSE (37)), and the homology model of the heNOS 
reductase domain was visualized in PyMOL. The PyMol measurement tool was used to perform 
the following measurements:  in 2WTR (66), the distance between the alpha carbon Lys400 and the 
alpha carbon of each amino acid of 26EFVE29; in 1NSE (37), the distance between Ser114 and 
each amino acid of the LVL motif in the PRRC region 103LVL104; and in the homology model, the 
distance between the alpha carbon of Ser600 and the alpha carbons of each amino acid in 
627RRKRK630.  
 
RESULTS    
Human eNOS Model Verification    
To produce and evaluate the quality of the eNOS reductase domain homology model, multiple 
NOS sequences from diverse species were aligned using the information provided from homologs 
with 3D structures (1TLL, 1F20, 3HR4) (67–69), producing the secondary structure informed 
MSA shown in figure 6. In order to model a 3D structure of human eNOS reductase domain, full-
length heNOS was first truncated to just the reductase domain (amino acids 492-1203) as shown 
in figure 6. The reductase domain was submitted to I-Tasser (62–64) for modeling. I-
Tasser returned 5 predicted models. Model 1 had the best confident score (-0.02), which was 10-
fold higher confidence than the next ranking model. To further evaluate Model 1 (Figure 7.a), it 
was superimposed onto rat nNOS reductase domain crystal structure 1TLL (67). As expected, 
Model 1 superimposes with low RMSD, 0.494 A onto 1TLL (67). One region of lower confidence 
is the auto-inhibitory (AI) insertion which has not been crystallized. The AI insertion is based 
on ab initio modeling. Still, 1TLL (67) has a partial a-helix that matches with the heNOS model’s 




Measurements of the Distance between Kinases Docking Motif and Phosphorylation Site 
In table 2 we show the calculated distances between each amino acid of the proposed 
docking motif on the substrate to the proposed phosphorylation site. Figure 8a-c shows an example 
of one measurement for each binding/phosphorylation pair. The positive control of Arrestin 2 and 
MEK shows distances varying between 30.2 Å and 37.5 Å. ERK and P38 are proposed to bind 
the pentabasic motif and phosphorylate eNOS at Ser600. The distance between 
the pentabasic motif and Ser600 ranges between 4.6 Å and 17.8 Å. The difference between the 
control and the pentabasic motif distances are significantly different (m=-22.05; p=<0.0001). JNK 
and P38 are proposed to bind the PRRC motif and phosphorylate eNOS at Ser114. The distance 
between the PRRC motif and Ser114 ranges between 18.5 Å and 23.7 Å. Again, the PRRC 
distances compared to the control are significantly different (m=-13.42; p=0.0037). The 
differences between the Pentabasic motif distances and the PRRC motif distances are calculated 




Figure 7: NOS Modeling Cartoon Depicting Nitric-Oxide Synthase Reductase Domain  
(A) eNOS model displaying the pentabasic region in blue. (B) eNOS model (gold) 




Taken together, the results help highlight the differences between the distances of where 
MAP Kinases dock and phosphorylate eNOS. Because there are only three crystal structures of 
NOS reductase domain (none of which are eNOS), designing a model of human eNOS reductase 
domain was 1) necessary for measurements and calculations, and 2) allows insights to the 
structural properties of eNOS. However, there are caveats that come with designing a model. The 
majority of the heNOS reductase domain model is based on homology modeling (specifically, the 
rat nNOS reductase domain (1TLL; 67).  The AI insertion, which encompasses both the proposed 
binding site at the KRRK motif and the Ser600 phosphorylation site, is based on ab initio modeling, 
making its position uncertain. A partial a-helix from nNOS (67) superimposes over the AI insertion 
of the model increasing our confidence in the model of the AI insertion. 
 
The AI insertion is based not only on ab initio modeling but also on the overall fold of the 
template protein. This also gives rise to uncertainty. For example, the distances between the 
pentabasic motif and Ser600 may vary based on phosphorylation at Ser615 and Ser635. 
Phosphorylation at one or both may repel parts of the AI insertion further or closer away from the 
phosphorylation site.  In addition, calmodulin binding near the AI insertion may move it from the 
bulk of the reductase domain.  
 
Figure 8: Measurement of the distances between kinases docking and phosphorylation sites  
(A) Crystalized structure of Arrestin2 depicting the calculated distances between Lys400 and 
Asp26 as a representative model. (B) Crystalized structure of bovine eNOS PRRC motif 
depicting the calculated distances between Ser116/114 and Lys104 as a representative model. (C) 
Model of heNOS depicting the calculated distances between Ser602/600 and Lys631 as a 
representative model.  
C A B 
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The most likely cause for 
the big differences in the 
binding/phosphorylation site 
distances between Arrestin2 and 
the other proposed MAP Kinases 
recognition sequence is that the 
sequence between 401 and 418, 
which includes the 
phosphorylation site, is not visible 
in 2WTR (66). I used the visible 
amino acid (Lys400) closest to the 
docking site to estimate the 
distance between the docking site 
and the phosphorylation site. 
Lys400 is thus 12 amino acids 
away from the phosphorylation 
site. 
 Although the bulk of the data in inclusive, it does appear that the distance between Ser600 
and the pentabasic motif is within a distance that coincides with the PRRC motif. In the results, 
there is a statistical difference between the distances of the PRRC and the pentabasic model. 
However, because the model may have conformational discrepancies there is not enough evidence 
to rule out the pentabasic or PRRC motifs as recognition sequences for MAP Kinases.  
 
  
Table 2: The distance measurements between kinases 
docking sites and proposed phosphorylation site. 
Amino Acid Pentabasic PRRC B-Arrestin 
Ser600-Arg627 4.6   
Ser600-Arg628 11.2   
Ser600-Lys629 12.7   
Ser600-Arg630 14.2   
Ser600-Lys631 17.8   
    
Leu103-Ser114  23.7  
Val104-Ser114  20.0  
Leu105-Ser114  18.5  
    
Lys400-Asp26   30.2 
Lys400-Phe27   33.9 
Lys400-Val28   35.0 
Lys400-Asp29   37.5 
Averages 12.1 20.7 34.15 
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Our lab previously published that ERK binds eNOS with high affinity (50). We followed 
by publishing that ERK phosphorylates eNOS at Ser600 in a time dependent manner in vitro and 
phosphorylation at Ser600 is a physiological occurrence (46). eNOS is heavily regulated through a 
number of other PTM and depends on co-factors and substrates to be catalytically active. These 
factors make eNOS a “difficult” protein to work with and purify. As discussed in chapter 1 eNOS 
requires heme, BH4, and zinc to stabilize the oxygenase domain as well as FMN and FAD to 
stabilize the reductase domain. Our eNOS is optimized for E. coli expression with a histidine tag 
for affinity purification.  
 eNOS catalyzes the conversion of L-arginine, molecular oxygen, and NADPH to NO and 
L-citrulline (see chapter 1). For this reaction to occur eNOS must contain high spin state heme (a 
final electron acceptor); this species of heme only exists when eNOS is in the dimeric form and 
when this occurs a Soret peak can be measured spectrophotometrically at 400nm. Originally, 
bovine eNOS was expressed in a proteinase-deficient E. coli strain BL21-DE3 (Novagen) with 
growing conditions optimized for the expression system; however, this expression regimen proved 
to be difficult in our hands. Herein we present our results improving eNOS production; using an 
optimized plasmid that expresses human His-tagged eNOS in E. coli. In addition to creating a new 
plasmid, we have also optimized our protocol for eNOS purification and we are working with 
human eNOS, which enables a better understanding of human regulatory issues. 
Hemoglobin and the Measurement of Nitric-Oxide 
The assay our lab uses to measure NO is the conversion of oxyhemoglobin to 
methemoglobin (70). Hemoglobin is a globular protein comprised of four subunits containing 
heme groups. The heme groups contain an iron (Fe) ion that coordinates with six sites, four of 
which are nitrogen atoms. The fifth coordination site is covalently bonded with histidine and the 
sixth coordination site determines the fate of the hemoglobin protein. Oxygen and other small 
molecules bind Fe and affect the electron structure and magnetic properties of hemoglobin (71). 
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 When molecular oxygen binds the sixth site of hemoglobin, it is termed oxyhemoglobin 
conversely, when hemoglobin is oxygen free it is considered to be deoxyhemoglobin. There are 
partial species of hemoglobin that binds other small molecules such as NO; in this case, the 
hemoglobin is termed methemoglobin. Because there is a spectrophotometric difference between 
oxyhemoglobin and NO-bound hemoglobin (methemoglobin), we can measure NO synthesis 
using the oxyhemoglobin to methemoglobin assay. When eNOS is incubated with oxyhemoglobin, 
the NO that eNOS produces coverts oxyhemoglobin to methemoglobin as shown in figure 1. This 
assay monitors the absorption difference between 401nm (oxyhemoglobin) and 421nm 
(methemoglobin) or just at 401nm (Figure 9). Over the years this protocol has enabled eNOS 
activity analysis in vitro and has been modified to enable NO detection in ex vivo experiments (72, 
73).  
 
Objective and Hypothesis  
Our objective is to understand how MAP Kinases influence the ability of eNOS to generate 
NO. As previously mentioned, ERK, P38, and JNK have all shown an ability to bind eNOS, 
however, there is conflicting evidence on how these kinases influence eNOS synthesis of NO. This 
Figure 9: Schematic representation of hemoglobin species and measurements in 
oxyhemoglobin to methemoglobin.  
Oxyhemoglobin can be measured at 421nm followed by two peaks at 532nm and 585nm 
(A&C) while the methemoglobin peak absorbance is at 401nm (B&C). As NO is 
synthesized oxyhemoglobin should be oxidized leading to less absorption at 421nm (D) and 
increase in 401 (E). Absorbance at 421 can be subtracted from absorbance at 401nm (F).  
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chapter aims to characterize how MAP Kinases phosphorylate eNOS and the influence that MAP 
Kinases have over NO production. 
 
EXPERIMENTAL PROCEDURES      
Materials  
Riboflavin 98%, Ampicillin, L-arginine, (6R)-5,6,7,8-tetrahydrobiopterin, bovine 
calmodulin, human hemoglobin, flavin adenine dinucleotide disodium salt hydrate, NADPH 
tetrasodium salt, acetylated-BSA, riboflavin 5′-monophosphate sodium salt hydrate, superoxide 
dismutase bovine (Catalog #9054-89-1), and catalase from bovine liver (Catalog #C1345), were 
all purchased from Sigma-Aldrich. Electrophoresis reagents, chambers, and tris-acetate 3-8% gels 
were purchased from Bio-Rad. 5-Aminolevulinic acid was purchased from Cayman Chemical. 
Terrific Broth, isopropyl-beta-D-thiogalactopyranoside, Tris-HCl, sodium chloride, imidazole, 
tween20, calcium chloride, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), magnesium chloride, β-
glycerophosphate disodium salt, glycerol, and dithiothreitol were all purchased from Genesee 
Scientific. Protease Arrest was purchased from G-Biosciences, and Slide-A-Lyzer Dialysis 
Cassette were purchased from Thermofisher Scientific. Monoclonal antibody against NOS3 (250 
µg/ml used at a 1:1000 dilution; Catalog#: 610297) was purchased from BD-Biosciences. 
Phospho-specific S600 (0.9mg/mL used at a 1:500 dilution; ABS1631) eNOS antibody was made 
in-house and can be purchased from Millipore Sigma. Phospho-specific Ser114 (1:500 dilution; 
Lot# 2973090) eNOS antibody was also purchased from Millipore. Human Phospho-eNOS 
(S1177) antibody was purchased from R&D Systems. cAMP-dependent Protein Kinase (PKA), 
Catalytic Subunit (lot #P6000L) was purchased from New England Biolabs. GST-purified MAP 
Kinases ERK (Lot #P1662-5) and JNK (Lot #X561-2) were purchased from SignalChem. His-





eNOS Purification  







50 mM Tris-HCl (pH-8.0), 500 mM NaCl, 10 mM Imidazole, 10% 
Glycerol, 6mM BME, 5-10ug, DNase I, 2x Protease Arrest, 
100M BH4, 0.5% Tween 20, 5M FAD, 5M FMN 
Buffer 
H 
50 mM Tris-HCl (pH-8.0), 500 mM NaCl, 10 mM Imidazole, 10% 
Glycerol, lmM BME, 5M FAD, 5M FMN 
Buffer 
I 
50 mM Tris-HCl (pH-8.0), 500 mM NaCl, 10 mM Imidazole, 10% 
Glycerol, lmM BME 
Desalt Buffer  
Buffer 
Z 
10mM Hepes (pH-7.4), 150mM NaCl, 0.05% Tween 20, 10% 
Glycerol, 1mM DTT 
 
eNOS Transformation and Inoculation  
The polyHis-pet19b.eNOS vector (Ampicillin resistant) optimized for E. coli was designed 
by Genewiz and verified in house by 5' NdeI and 3' XhoI restriction digest. After verification 
pet19b.eNOS was transformed into Hi-Control competent cells transfected with chaperons CPN 
10 and 60 from the Artic Express strains (Agilent technology), plated on ampicillin and gentamicin 
containing plates for 13 hours and stored at 4º-8ºC up to 5 days. Single colonies were grown in 
50mL cultures overnight at 37 ºC (220 rpm). The next day 13mL of the overnight solution was 
used to inoculate 2.8 L Fernbach flask flasks each containing 1L of terrific broth (47g/L) and 
supplemented with ampicillin (100 ug/mL final concentration), riboflavin (1.5 mg), and 
aminolevulinic acid (167.6 mg). Flasks were placed in an orbital shaker and allowed to grow at 
37ºC (220 rpm) in the dark. The OD600 was checked periodically during the growth period until it 
reached an OD600 of 0.8–1.0 (4–5 h) then the cultures were supplemented with adenosine-50-
triphosphate (ATP, 100mg) and isopropyl-beta-D-thiogalactopyranoside (IPTG, 1 mM final 
concentration, to induce the T7 promoter). The cells were incubated for 16–48 h at 23 ºC (220 
rpm) again in the dark. Bacteria were harvested and pelleted by centrifugation using a FiberLite 
F6 6 1000 rotor at 4ºC (7,000 rpm) for 10 min and stored in the -80 ºC 
 
eNOS Expression and Purification 
The pellets (typically 2) were thawed, immediately transferred into resuspension buffer G, 
vortexed and resuspended at 4ºC, then lysed using a french press. The lysates were then centrifuged 
at 4ºC (18,000 rpm) for 20min. The supernatants were incubated with 1mL of TALON cobalt resin 
beads for 20-30 minutes using buffer G without the DNase, Lysozyme, Tween 20, and DNAse. 
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The beads were washed with buffer H three times to wash away nonspecific proteins. Elution of 
histidine-tagged protein was accomplished using buffer I and collected in 1mL fractions. A subset 
of the elution was subjected to SDS-PAGE with Coomassie blue staining and/or immunoblotting 
analysis. Fractions with higher protein concentrations (determined by crude pierce 600 nm protein 
assay) were dialyzed overnight using a Slide-A-Lyzer dialysis cassette in buffer Z spiked with 
1mM DTT. It is important to note all steps of the purification were performed at 4 ºC, and purified 
eNOS was stored at -80ºC. Protein homogeneity was confirmed using SDS-PAGE with Coomassie 
blue staining and western blot with anti-eNOS antibody at a 1:1000 dilution. The final protein 
concentrations were measured in each fraction by total protein (pierce 660nm assay; (75)) 
concentration and by heme concentration. Concentrations of heme-containing eNOS were 
determined from the absorption spectrum of the protein using the extinction coefficient E400 nm 
=100 mM-1 cm-1 for the ferric enzyme (70). 
 
eNOS Binding  
Biolayer Interferometry (BLI) experiments were performed using a FortéBio (Menlo Park, 
CA, USA) Octet QK using streptavidin sensors. Assays were done in black 96-well plates at 25°C; 
200M volumes were used in each well. Biotinylated Tat-CaM (provided by the McMurry lab 
(50)) in a 1M solution was loaded onto sensors for 300s followed by baseline measurements in 
NEB binding buffer (pH 7.4; 10mM Hepes, 0.15M NaCl, 100mM CaCl2, 10% Glycerol and 1mM 
DTT) for 300s. Association was measured by dipping sensors into solutions of purified eNOS 
sample diluted to final concentrations of 31.5nM-2M using NEB buffer and was followed by 
moving sensors to 0.5mM EDTA buffer to monitor dissociation. 
 
Kinase Assays 
Kinase reactions were performed in 20 mM HEPES (pH 7.4 at RT), 0.5 mM DTT, 5 mM 
MgCl2, 0.5 mM ATP, and 10% glycerol. eNOS was used at various concentrations reported in the 
figure legends. Reactions were incubated for up to 60 minutes with various concentrations of 
kinases (also reported in figure legends) at 22-25 ºC. The reactions were quenched in 1x sample 
buffer spiked with 25mM DTT and boiled for 5 minutes unless otherwise stated. Samples were 
electrophoresed by equal volume (indicative of equal protein) western blotted and probed with 
either anti-eNOS (Bb-Biosciences) at a 1:1000 dilution, eNOS phospho-specific S600 (described 
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previously (46)) at a 1:500 dilution, or eNOS phospho-specific S114 (Millipore) at a 1:500 
dilution.  
 
Western-Blotting and Detection  
Either 3-8% gradient tris-acetate gels (76) or 10% SDS-page gels were loaded with 30L 
(1.71g) or 20L (1.14g) volume respectively. Gels were transferred to PVDF membranes and 
transferred for either 2 hours (Tris-acetate) at 40V or for 1 hour at 100V (SDS-page) at RT. 
Samples were blocked with one block (77) for 30 minutes and incubated with either Phospho-
specific antibodies pSer114 or pSer600 at 4ºC for no less than 14 hour or non phospho antibodies 
anti-eNOS for 2-4 hours at room temperature. The next day the blots were brought to RT for at 
least 30 minutes before being washed with 1X TBST for 10 minutes (3x) and then probed with 
fluorometric secondary antibody (Li-Cor IRDye®) for 45-60 minutes. The blots were washed again 
in TBST as described before and then visualized with a Li-Cor Odyssey.   
 
Nitric-Oxide Synthesis Measurement  
Kinase assay reactions were performed as described above and quenched on ice until ready 
to proceed (typically not more than 10 minutes). NO synthesis was measured using the 
spectrophotometric oxyhemoglobin to methemoglobin assay. The assays were performed at 25 °C 
in a BioTek 96-well UV-visible spectrophotometer. eNOS was assayed at concentrations depicted 
in figure legends, in a 100-μl total volume per well. Unless otherwise stated, the final 
concentrations of the assay constituents were 1μM FAD, 1μM FMN, 10% glycerol, 12nM BH4 
(stock BH4 was made with oxygen free water and stored with 30 mM dithiothreitol), 100 μM L-
arginine, 10 mM Tris-HCl, pH 7.5 at 25°, 250μM CaCl2, 0.20 mg/ml BSA, 0.31mg Hemoglobin, 
7-10U Superoxide Dismutase, 7-10U Catalase, and 17μg CaM (78). The reaction was initiated by 
addition of 200M NADPH reconstituted in Tris-HCl (1.4M pH 7.5RT). OD was read at 401nm, 
421nm, and 340nm. Prior to the addition of NADPH, kinetic readings were taken for 1 minute at 
15 second intervals. The NADPH was then added and kinetics readings were taken for 10 min at 
15 second intervals.   
 
eNOS Activity Calculation  
To calculate eNOS activity the change in absorbance/unit time was divided by the 
extinction coefficient (77,200 M-1 cm-1 for 401nm-421nm or 38,600 M-1 cm-1 for 401nm alone). 
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This yielded eNOS activity in units of molar change/unit time. The value was then multiplied by 
the final reaction mixture volume and divided by the weight of the protein in that volume and 













Purifying Active eNOS 
Pet19b was used to express catalytically active human recombinant eNOS in Hi Control 
strains co-transformed with chaperons CPN 10 and CPN 60 using the T7 promoter. The cells were 
induced by IPTG and the crude supernatants were purified over TALON Cobalt resin. The desalted 
elutions showed a visible band with a molecular mass of 150 kDa via Coomassie Blue-stained 
SDS gels (Figure 10.A). The spectra of purified ferric eNOS was desalted and spiked with 2mM 
BH4 shown in figure 10.B. A Soret peak can be found above 400nm and shifts to the right in less 
concentrated eNOS fractions. Biolayer interferometry binding data shows that eNOS binds 
calmodulin with high affinity as evinced between 630sec-930sec, stays tightly bound in the 
presence of buffer (930sec-1230sec), and only dissociates in an EDTA buffer solution (1230sec-
1530sec) as shown in figure 10.C. 
 
eNOS is Differentially Phosphorylated in vitro 
 Figure 11 depicts time dependent eNOS phosphorylation via western blotting with 
pSer600, pSer114, and anti-eNOS antibodies. eNOS (3.3M) was incubated independently with 
different MAP Kinases, either ERK (15M), JNK (28M), or P38 (5.7M) for up to 60 minutes 
and quenched as mentioned previously. The reactions were loaded onto a 3-8% Tris-acetate gel. 
The results (Figure 11.A) displayed differential phosphorylation in a time-dependent manner. ERK 
showed preferential phosphorylation at Ser600 while JNK preferentially phosphorylated eNOS at 
Ser114; P38 phosphorylated both sites. This experiment was performed in triplicate using an 
enzymatic ratio (based on activity) of kinase to eNOS. Figure 11.B shows 3M eNOS incubated 
with 1.2M JNK, 1.2M ERK, or 7M P38 independently. Again, ERK showed preferential 
phosphorylation at Ser600 while JNK preferentially phosphorylated eNOS at Ser114; P38 
phosphorylated both sites. 
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 eNOS activity changes are different between the MAP kinases  
The activity of eNOS after pre-incubation with active MAP kinases was calculated at both 
401nm and at 410nm-421nm. eNOS (3.3uM) was incubated with 1.2M ERK and JNK for 30 and 
50 minutes and quenched on ice. 
After a 30 minute kinase assay with 
JNK, eNOS activity showed a 31% 
(N=3) decrease in activity at 401nm 
as compared to a 33.8% (N=5) 
decrease in eNOS incubated with 
ERK; highlighted in figure 12.A. 
After 50 minutes, figure 12.C 
shows there was no significant 
change in eNOS activity when 
incubated with JNK (N=4) while 
ERK incubation decreased eNOS 
activity by 85% (N=4; p=0.0168) 
measured at 401nm. eNOS activity 
measured by 401nm-421nm after a 
30 minute kinase assay resulted in a 
33.5% (N=5) decrease in activity 
after ERK incubation and a JNK did 
not significantly impact eNOS 
activity as there was a 14% (N=3) 
decrease in activity; shown in figure 
12.C. However, after 50 minutes 
eNOS activity was not significantly 
altered (Figure 12.D) by JNK or 




Figure 10: Purified eNOS absorbance spectrum from 
Hi Control cells co-transformed with chaperones CPN 
10&60 and eNOS.  
 
(A) SDS-PAGE gel stained with commassie brilliant 
blue reagent. Loading order: Marker Lane 1, Elutions 1 
and 2 are lanes 2 and 3 respectively. (B) Absorption 
spectrum of his-tagged elutions 1-3. (C) Biolayer 
interferometry data displaying eNOS (31.5nM-2uM) 
binding to biotinylated Tat-CaM for 300 seconds, 
remaining bound when incubated with buffer and 
finally dissociated with 0.5mM EDTA buffer. 
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eNOS activity is not inhibited by ERK in different conditions 
ERK and P38 (Figure 
13) do not inhibit eNOS 
activity. ERK was purified in 
house without the presence 
glutathione (GSH) and 
incubated with eNOS. PKA 
incubation with eNOS (Figure 
13.a; N=4) served as a positive 
control for the assay showing a 
78% increase in eNOS activity. 
ERK treated eNOS (N=3) 
shows a 28% non-significant 
activation of eNOS activity 
(Figure 13.B), while P38 
treated eNOS (N=3) shows 
11.5% non-significant increase 
in eNOS activity after a 30 




A years’ worth of work 
went into learning how to 
purify active eNOS. 
Throughout the process, there were setbacks in understanding what factors are necessary for eNOS 
stabilization. This difficult process was necessary and shows the complexity behind eNOS folding 
and stabilization. BDP BL21 cells were first used for eNOS purifications, and while these cells 
bountifully expressed eNOS there was no heme incorporated into the protein. Our interpretation 
is that the precursor δ-aminolevulinic acid is rendered useless in the presence of blue light (hence 
the requirement for the dark) frequencies. When eNOS was expressed in the dark we saw a change 
Figure 11: MAP Kinase differently phosphorylates eNOS  
 
Western blot of eNOS incubated with JNK, P38, ERK for 
5 & 60min, sample buffer. Immunoblotted for phospho-
specific antibodies Ser600/602 and Ser114/116 (Millipore). 
Loading Control is anti-eNOS (BD-Biosciences). (A) 
eNOS incubated with excess amount of kinase and (B) 
eNOS incubated with an enzymatic ratio of kinase to 
substrate. (Ser114/600 is human numbering and Ser116/ 




in pellet color (dark brownish-reddish 
appearance) and a heme Soret peak at 
approximately 415nm to 420nm. 
Next, a variety of expression systems 
were tested and the best outcomes were found 
using hi-control cells in the dark with the artic 
express chaperones; this system has enabled 
the production of full length eNOS. This will 
allow our lab to study the population of eNOS 
that exists as a dimer versus the amount that 
exists as a monomer from a purification. We 
hypothesize that the monomer population is 
misfolded and cannot form a dimer to produce 
NO. We saw these characteristics in the eNOS 
that was purified from other strains. We 
hypothesize that the majority of the eNOS 
from the purification existed as a monomer 
and through heme was bound eNOS could not 
form a dimer to produce NO because of 
Figure 12: ERK inhibits eNOS activity while 
JNK does not.  
(A-D) In the presence of GSH, ERK negatively 
impacts eNOS ability to produce NO (as 
mentioned in text) while JNK does not. 3.3uM 
eNOS was incubated independently with either 
7.5nM JNK or 1.2nM ERK for 30 or 50 
minutes. Absorbance at either 401nm (A&B) 
or 401nm-421nm (C&D) was used to calculate 
activity.  
Figure 13: ERK and P38 do not significantly alter the activity of eNOS.  
(A-C) 1.2M PKA, 1.2M ERK, and 3M P38 were incubated with 3.3uM eNOS for 30 
minutes. Absorbance at 401nm-421nm was used to calculate activity.  
C A B 
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misfolding. Nevertheless, we did succeed in purifying active dimeric eNOS that we can currently 
use for activity experiments.  
Our active eNOS allowed the above experiments to explore the manner in which MAP 
kinases interact with eNOS. Our previous data originally showed that ERK binds eNOS (50) 
building on data from the Michel lab (53) that showed ERK was interacting with eNOS in cells. 
The following year we published that ERK phosphorylates eNOS at Ser600 in a time dependent 
manner and showed that phosphorylation at Ser600 is present in cells. We now present that P38 and 
JNK phosphorylate eNOS in addition to ERK and that they do so in a differential way. This 
supports our original Mass Spectrometry data that did not find eNOS to be phosphorylated at Ser114 
by ERK (46). Originally, we exceeded the enzymatic ratio of kinase to substrate to ensure that 
eNOS phosphorylation was occurring in vitro as shown in figure 11.A. We then backed down to 
an enzymatic ratio of kinase to substrate based on calculated activity and still, results show eNOS 
phosphorylation by MAP kinases results in different residues being preferentially targeted in figure 
11.B.  
Once we realized that MAP Kinases differentially phosphorylate eNOS we hypothesized 
that MAP Kinases might differentially alter eNOS activity. However, when we originally tested 
MAP Kinases ability to modulate eNOS activity the data was inconclusive. Measurement at 401nm 
is designed to exclusively measure the formation of methemoglobin by NO. However, when we 
compared the 401nm data alone to the 401nm-421nm data there was a number of inconsistencies. 
Those inconsistencies suggested that oxyhemoglobin is oxidized overtime but not by NO. When 
we first started refining the protocol for measuring 401nm-421nm we could not understand how 
under the same conditions the assay would give us inconsistent results. Originally, we assumed 
that there was another species of hemoglobin that we could not spectrophotometrically test. At that 
point, we tested adding SOD and Catalase to ensure that any superoxide formation would be 
converted to water and prevent (lessen) interference with the assay. This appeared to work for a 
while, however, we ran into another problem.  
The critical issue of concern was that when our lab first did these assays they found that 
ERK decreased eNOS activity up to 60% (46), which was unreproducible in our current hands. 
However, there have been several changes – our source of eNOS is different and we are using 
slightly different assays to obtain the data. However, with a change in the results, we needed to be 
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very careful. We then began to reanalyze our data with calculating activity using 401nm 
exclusively (as others have done previously (78)) and sure enough, we calculated a 40-80% 
decrease in eNOS activity when incubated with ERK or JNK but not P38 and PKA. P38 incubation 
with eNOS consistently shows no effect on altering eNOS activity throughout all experiments. 
PKA incubation beforehand has also consistently produced enhanced NO synthesis. We then went 
back to look at the storage buffer of the ERK and JNK from SignalChem and realized that the 
buffer contains 10 mM glutathione (GSH). The kinases are GST-tagged and they do not desalt the 
GSH from the buffer. GSH has shown to be a potent 
inhibitor of eNOS in oxidative conditions via eNOS 
glutathionylation at Cys689 and Cys908 and the 
subsequent uncoupling of eNOS to produce 
superoxide (79). Active P38 was produced in-house 
and is His-tagged, one reason why P38 incubation 
with eNOS might be different.   
 
We are now purifying active ERK in-house. 
When repeating the experiments with His-ERK and 
His-P38, also purified in our lab we saw small non-
statistical increases in eNOS activity (figure 13). It is 
possible that the changes in activity are due to other 
interactions such as the binding of kinases 
themselves changing activity or other 
phosphorylation sites that are shared targets of ERK 
and P38. For example figure 14 shows bovine eNOS 
(1NSE 37) Oxygenase domain. If JNK were to bind 
to the PRRC motif (green and blue), it could interfere 
with the flow of electrons to the heme center from the 
pocket (red circle). Furthermore, JNK binding could impact the ability of L-arginine and BH4 to 
freely flow through. Therefore, our continuing work aims to purify JNK in house and understand 
how JNK modulates eNOS activity.  
 
 
Figure 14: Bovine endothelial nitric-oxide 
synthase 
Depicts bovine oxygenase domain. 
Heighted in Blue is the PRRC sequence 
and specifically in green is a putative LVL 
MAP Kinase recognition sequence. The 
yellow highlight is the SP that JNK 
phosphorylates. The blue box represents 
the proposed JNK binding site and the red 
circle is the catalytic domain contain 
binding sites for heme, BH4, and L-
arginine.  
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 eNOS is a cellular target of multiple signaling cascades. Our previous work showed that 
eNOS is endogenously phosphorylated at Ser600 in bovine aortic endothelial cells (BAEC). At that 
time, we did not try to manipulate levels of Ser600 in cells; since then, nothing we have treated cells 
with has altered the level of Ser600 phosphorylation besides a pan cyclin dependent kinase (CDK) 
and ERK1 inhibitor, which decreased levels. While these results with the inhibitor could strengthen 
our argument that ERK endogenously phosphorylates eNOS in cells. The lack of change of cellular 
status of Ser600 with known activators of ERK contradicts this interpretation. This provided an 
exciting alternative about CDK as a physiologic Ser600 kinase, but our focus was on MAP kinases. 
The hypothesis at the beginning of this work was that MAP Kinases P38, ERK, and JNK would 
decrease eNOS activity through phosphorylation at Ser600 and/or Ser114. We hypothesized that in 
cells there would be a population of eNOS phosphorylated at both activating and inhibitory sites, 
creating “antagonistically phosphorylated” eNOS. However, our results necessitated a change in 
our hypothesis.  As presented in chapter 3 we found that in vitro MAP Kinases are not altering 
Figure 15: Graphical representation of the dually phosphorylated eNOS hypothesis  
PKA phosphorylates eNOS at Ser1177 increasing eNOS activity while we propose MAP Kinases 
P38, JNK, and ERK phosphorylate eNOS at Ser600 or Ser114 and have no noticeable effect on 
eNOS activity. However we question how phosphorylation at Ser1177 congruently with 
phosphorylation at Ser600/Ser114 affects eNOS activity.  
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eNOS activity. Therefore, we have reworked our hypothesis (Figure 15) to understand if there is a 
subset of eNOS that can exist dually phosphorylated at Ser1177 and Ser600. It has been suggested 
that protein kinase PKA phosphorylates both Ser1177 and Ser633 (55) and we observe in vitro that 
ERK and P38 phosphorylate Ser600. Would phosphorylation concurrently at both sites lessen the 
amount of NO produced, or enhance it? A number of studies show that perturbations of eNOS 
phosphorylation are reported in a number of diseases and they emphasize its importance. 
Furthermore, we understand that NO signaling is misregulated in disease models (6, 48, 80) and 
that eNOS phosphorylation at Ser1177 helps to alleviate symptoms found in disease models (81). 
However, we do not understand how and if a dually phosphorylated eNOS at Ser1177 and Ser600 
has any physiological relevance. We postulate that this may be an endogenous mechanism to fine-
tune NO production in cells for growth and proliferation. 
 
Objective and Hypothesis  
In the present study, we observe how ERK and pERK interact with eNOS under different 
conditions in HMEC-1 cells. We also explore how phosphorylation at Ser600 happens concurrently 
with activating site Ser1177, creating a subset of eNOS that is dually phosphorylated. These results 
underscore the importance of MAPK interactions with eNOS showing that each MAPK creates a 
unique phosphorylation pattern and probably a unique protein-protein interaction pattern. 
 
MATERIALS AND METHODS  
Materials  
Human Microvascular Endothelial Cells (HMEC-1) were purchased from ATCC. The L-
glutamine, trypsin, epidermal growth factor (EGF), and Fetal Bovine Serum (FBS) were purchased 
from Atlanta Biologicals. The hydrocortisone, MCDB 131 media, DMEM low glucose media, and 
insulin were purchased from Sigma Aldrich. Protein G Dynabeads were purchased from 
Thermofisher Scientific. Monoclonal antibody against NOS3 (250 µg/ml at a 1:1000 dilution; 
Catalog#: 610297) was purchased from BD-Biosciences. Phospho-specific Ser600 (0.9mg/mL at 
a 1:500 dilution; ABS1631) eNOS antibody was made in-house and can be purchased from 
Millipore Sigma. Phospho-specific Ser114 (1:500 dilution; Lot# 2973090) eNOS antibody was 
also purchased from Millipore. Phospho-eNOS (Ser1177) (C9C3) Rabbit mAb #9570 antibody, 
Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (E10) Mouse mAb #9106 and p44/42 MAPK 
(Erk1/2) Antibody #9102 were purchased from Cell Signaling Technology 
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Human Microvascular Endothelium Cells (HMEC-1)  
Frozen HMEC-1 cells were thawed, centrifuged at 1000RPM for 5 minutes (30°C) to 
remove any storage DMSO, and resuspended into warm completed growth media (MCDB131 
supplemented with 10% FBS, 1g/mL Hydrocortisone, 10mM Glutamine, 10ng/ml Epidermal 
Growth Factor). Once the cells were 85-90% confluent, the cells were rinsed in trypsin (30sec) 
and trypsinized (3mL for T75) for 3 to 5 minutes. Note that HMEC-1 cells strongly adhere to flask 
surfaces. After the cells began to detach (as seen under a compound light microscope) they were 
quenched with at 1:3 ratio (trypsin to full media) using full culture media and centrifuged at 
1000RPM for 5 minutes (30°C). The old media was aspirated and the cell pellet was resuspended 
with full media. Cells were plated at a 1:8 dilution and kept for up to 15 generations. Note, the lab 
has changed this procedure, centrifugation is used for thawing cells, but in routine passages, as 
directed by the ATCC the cells are just diluted to pass.   
 
Harvest and Preparation of Cell Lysates 
HMEC-1 cells are kept as previously described. In preparation for an experiment, in most 
cases the cells were serum starved; old growth media was removed and replaced with DMEM low 
glucose media for 3 to 4 hours prior to treatment. Cells were then treated with either 10ng/mL EGF 
or 500nM insulin; see figure legends for details. After treatment, the cells were washed with cold 
PBS, harvested (by scrapping) into pre-chilled lysis buffer (1% Igepal, 0.5% Triton-X-100, 1.5mM 
MgCl2, 150mM NaCl, 50mM Tris (pH7.4 at 4°C), and 10 glycerol) supplemented with 1x protease 
inhibitor (ThermoScientific #1861278), 1M micro-cysteine, and 2M sodium vanadate and 




The lysates were thawed on ice, centrifuged at 12,000RPM (4°C) for 15 minutes, and the 
supernatants were transferred to a fresh microcentrifuge tube. An aliquot of the lysate (280g) was 
reacted with either 0.5g of pSer600 antibody or 0.7g of pSer1177 antibody for 30 minutes at 
4°C, and then incubated with protein G- Dynabeads for an additional 45minutes. The samples were 
eluted in 2x sample buffer spiked with 100mM DTT and boiled for 5-7 minute. The post-bind 
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samples were subjected to sequential IP with anti eNOS antibody and eluted in the same manner. 
The samples were analyzed via immunoblotting imaging.  
 
RESULTS 
ERK and not pERK bind eNOS in HMEC-1 
HMEC-1 cells were seeded in 10cm plates and treated with 10ng/mL EGF for 5 and 10 
minutes. They were harvested, lysed and split into two parts one was IPed with pSer600 the other 
pSer1177 antibodies. The IP elutions were probed for either anti eNOS (top red), pSer1177 (top 
green), ERK (bottom red), or pERK (bottom green) as shown in figure 16. The top left panel shows 
that eNOS is dually phosphorylated even in the presence of EGF there is a population of eNOS 
that is phosphorylated both at Ser1177 
and Ser600. The top right panel shows 
the loading control in green and that 
there is a subset of eNOS that is 
phosphorylated at Ser1177. ERK 
endogenously binds eNOS and when 
treated with EGF for 5 or 10 minutes 
the complex dissociates as shown in 
the bottom panel to the left – the red 
doublet lacking pERK reactivity 
completely. Furthermore, ERK does 
not bind eNOS phosphorylated at 
Ser1177 and it appears that pERK does not co-immunoprecipitate with phosphorylated eNOS.  
 
eNOS is phosphorylated through multiple signaling outputs in HMEC-1 cells 
HMEC-1 cells were seeded in 15cm plates and treated with 500nM insulin for 60 minutes. 
They were harvested, lysed and IPed with pSer600 and sequentially IPed with anti eNOS. The IP 
samples were probed for either anti eNOS or pSer1177 as shown in figure 17. Cells treated with 
and without insulin shows that eNOS is phosphorylated by multiple signaling inputs (EGF, insulin) 
through phosphorylation at Ser600 and Ser1177. After the portion that had been IPed with pSer600 
was removed the post bind was IPed with anti-eNOS and both IPs were probed with pSer1177. 
This shows that there is a population of eNOS in cells that are not phosphorylated at Ser600 as 
Figure 16: ERK binds differentially phosphorylated 
eNOS.  
 
ERK binds eNOS after phosphorylation at Ser600, 
whereas active ERK does not interact with Ser1177 
phosphorylated eNOS or EGF treated cell. 
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shown in the top right panel of figure 8. 
The bottom panel shows the loading 
control and the lysate samples before the 
IP is shown in the center.  
 
DISCUSSION  
Previous work from our lab 
showed that eNOS phosphorylation at 
Ser600 is endogenous in primary BAEC 
(46). This work takes a closer look into the 
signaling inputs that regulate eNOS in 
HMEC-1 cells. Our results show when we 
treated cells with 10ng/mL EGF we saw 
ERK dissociate from eNOS; we 
hypothesize that EGF treatment leads to 
increased phosphorylation of eNOS at 
Ser633 through increases in PKA activation and that displaces the ERK and/or prevents new 
interactions. We have also shown from chapter 3 that ERK phosphorylates eNOS at Ser600 in 
vitro and yet in ex situ experiments, we were not able to capture a pERK binding to eNOS. We are 
not sure how to interpret that result however, one thought is the interaction between pERK and 
eNOS is unstable and the environment that we lyse and IP cells with causes eNOS and pERK to 
dissociate. Maybe a proximity ligation assay would help us gain more insights into this 
phenomenon in situ.  
The data from figure 8 also hints that there are different subsets of eNOS that have different 
phosphorylation patterns. The lysates were first IP’ed with Ser600 and that captured dually 
phosphorylated eNOS with Ser1177. However, the remaining post bind was sequentially IP’ed with 
anti-eNOS showing that there is a subset of eNOS that is not phosphorylated at Ser600 and a subset 
of eNOS that is not dually phosphorylated at both Ser600 and Ser1177. Characterizing the events that 
lead to eNOS phosphorylation at Ser600 is a future step that is currently in progress will be 
discussed a bit in chapter 5. However, figure 17 provides further evidence that eNOS is a target of 
multiple-signal inputs, as has been suggested widely in the literature. The literature suggests that 
Figure 17: eNOS is phosphorylated through 
multiple signaling outputs in HMEC-1 cells. 
Immunoprecipitation analysis of modified eNOS 
Ser1177 and Ser600. HMEC-1 cells at 80% 
confluence were treated with 500nM Insulin for 60 
min. The resulting lysates were sequentially 
immunoprecipitated using anti-pSer600 followed 
by anti-eNOS. Green panel shows anti-pSer1177 
antibody staining; red shows anti-eNOS antibody 
staining. (Ser114/600 is human numbering and 
Ser116/602 is bovine). 
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treatment with insulin promotes increase Ser1177 phosphorylation through the PKA or AKT and 
we hypothesize that ERK promotes phosphorylation at Ser600. This may suggest cross talk between 
these pathways and eNOS may be involved in some capacity. This research beings to highlight 




Chapter 5: Conclusions, Future Directions, Integrative Statement, and 
Acknowledgments  
 
CONCLUSIONS & FUTURE DIRECTIONS 
Our study has furthered our understanding of the complex modulation of eNOS. 
Specifically, we have shown that MAP Kinases have distinct modes of interaction with eNOS and 
have unique overlapping phosphorylation targets on eNOS. This began with successfully 
designing and verifying a model of the human eNOS reductase domain to use in determining if 
MAP Kinases can bind to the pentabasic motif within a distance that allows for subsequent 
phosphorylation. Even though our data remains inconclusive, it did provide insights into the 
interaction, allowing us to interpret that MAP Kinases bound to the pentabasic or PRRC motif 
would enable phosphorylation at the Ser600 site or Ser114 site respectively. We hope to better 
understand these interactions by characterizing the binding kinetics of MAP Kinase and the 
predicted eNOS binding sequences. Specifically, we intend to design peptides of the auto-
inhibitory and PRRC motifs for in vitro analysis using biolayer interferometry. Also as future 
directions, we aim to understand if there are any other known crystal structures of substrates 
(known to bind MAP Kinases) to use as a control. Though MEK is upstream of ERK, MEK 
phosphorylation capacity may be further than MAP Kinases ability to phosphorylate their 
substrates. Therefore, having a MAP Kinases control could help us better understand the distances 
from table 2. 
The bioinformatics data was useful in understanding that MAP Kinases could have two 
different sites of interaction supporting our data that shows that the kinases differentially 
phosphorylate eNOS. It was our hypothesis that eNOS phosphorylation and subsequent 
modulation in activity is dependent on where MAP Kinases bind. Our results show that MAP 
Kinases differentially phosphorylate eNOS in vitro (Figure 11) however, understanding this 
interaction in terms of activity proved more difficult for a number of reasons. MAP Kinases do not 
alter eNOS activity, however much testing still needs to be completed on the topic. GSH was a 
potential set back and as we work to remove GSH from all of our active kinases, our ability to 
quantify each kinases specific activity proves difficult and is an aim for the future. What is slightly 
confusing is that incubation of eNOS with these MAP kinases shows a consistent slight (non-
statistical) activation in activity. Another future aim is to determine if and how MAP Kinases 
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binding eNOS may alter its activity specifically if MAP Kinases binding eNOS alter the flow of 
electrons through the reductase domain.   
While eNOS activity is not altered by MAP Kinases in vitro we do see evidence that 
phosphorylation at Ser600 might be physiologically relevant. We have shown that eNOS is 
phosphorylated by multiple signaling outputs in cells and have also shown that phosphorylation at 
Ser600 happens congruently with phosphorylation at Ser1177. We have also shown that the MAP 
Kinase ERK binds differently to phosphorylated vs. unphosphorylated eNOS. This shows that 
eNOS might be at the center of a larger pathway and have another function from producing NO. 
This MAP Kinase-eNOS interaction is an area of intense interest in the field. As an example, one 
paper suggests that eNOS acts as a scaffold protein and hypothesizes that loss of eNOS contributes 
more to inflammation than reducing the amount of NO eNOS can produce (82). This suggests 
eNOS importance in cells exceeds the regulation of NO. However, as our last future aim, we do 
want to characterize how dually phosphorylated eNOS impacts NO production. We want to 
understand if phosphorylation at Ser600 after eNOS is already phosphorylated at Ser1177 causes a 
dimmer-switch where the enzyme produces various outputs of NO depending on the varied 
phosphorylation/other posttranslational modifications present. Taken together, we have presented 
that MAP Kinases interact with and likely influence eNOS actions in cells and contributed to the 
growing literature that eNOS is a highly regulated enzyme accepting various inputs to determine 
how much NO to make and begin a signaling cascade anew.  
 
INTEGRATIVE STATEMENT 
The dysregulation of eNOS and NO production has been shown in a number of disease 
modes such as T2DM, Alzheimer’s, Cardiovascular Disease, Inflammation, and more. Our 
research could be implemented in a number of ways. By understanding how eNOS works and the 
mechanism of NO production in cells will enable identification of pharmaceutical targets, more 
translational studies and ultimately the initiation of clinical trials. Furthermore, this thesis 
combines multiple techniques including bioinformatics/computational, analytical chemistry, 
biochemistry, enzymology, statistics, cellular, organismal, and more, and utilizing this integration 
has truly made me a better scientist. Finally, reactive oxygen species and reactive nitrogen species 
are important in a number of areas of science, particularly environmental studies. Exposure to 
industrial levels of nitrogen oxides can lead to death by collapse, burning, and swelling of 
39 
respiratory tissues. In plants, exposure to high levels of nitrogen dioxide and monoxide is 
dangerous. Furthermore, they contribute to acid rain formation which in turn damages vegetation 
and water bodies. Understanding how nitrogen oxides work could possibly lead to different ways 
to combat air pollution. 
 
ACKNOWLEDGMENTS 
I would like to give a special thanks to the Department of Molecular and Cellular Biology 
and the Peach-State Bridges to the Doctorate program at Kennesaw State University for supporting 
me. I am extremely grateful for my thesis advisor/mentor/lab mom Dr. Carol Chrestensen for your 
unconditional support in guiding me throughout the program and preparing me for my next steps. 
I would also like to thank my thesis committee members Dr. Susan Smith, Dr. Scott Nowak, and 
Dr. Johnathan McMurry. Thank you Dr. Smith for helping me become more concise with verbiage 
and also for guiding me in learning bioinformatics techniques. Dr. Nowak always provides me 
with a much needed laugh and also provides me with realistic expectations for my goals. Special 
thanks to Dr. McMurry for recruiting me to KSU and for unconditionally looking out for my best 
interests. Thank you Dr. Melanie Griffith, Dr. Lisa Ganser, for also supporting me throughout the 
program. Special thanks to the Chrestensen and McMurry lab – Hao Qiao, Kersten Forsberg, 
Morgan Watson, Lydia Wade, Brady Wells, Kevin Patel, Bradley Jenkins, Chris Alcott, Dr. Julia 
LeCher, and Dr. Daniel Morris. I would also like to thank my friends and personal mentors that 
are always supporting me – Tequila Porter, Lindsay Brown, William Commins, MSIB cohort, 
Jordan Moreland, and Jason Hunziker. Finally, I would like to thank my family Melissa Solone, 
Bell Solone, Tyrell Solone, Quinton Solone, and everyone else that has helped me in any way 





1.  Benjamin EJ, et al. (2018) Heart disease and stroke statistics - 2018 update: A report 
from the American Heart Association doi:10.1161/CIR.0000000000000558. 
2.  Mozaffarian D, et al. (2015) Heart disease and stroke statistics--2015 update: a report 
from the American Heart Association. Circulation 131(4):e29-322. 
3.  Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2017. 
Atlanta, GA: Centers for Disease Control and Prevention, U.S. Dept of Health and Human 
Services; 2017 (2015) (2017) doi:10.1161/CIR.0000000000000152. 
4.  Hsu M-F, Meng T-C (2010) Enhancement of Insulin Responsiveness by Nitric Oxide-
mediated Inactivation of Protein-tyrosine Phosphatases. J Biol Chem 285(11):7919–7928. 
5.  Naseem KM (2005) The role of nitric oxide in cardiovascular diseases. Mol Aspects Med 
26(1-2 SPEC. ISS.):33–65. 
6.  Sandoo A, Veldhuijzen van Zanten JJCS, Metsios GS, Carroll D, Kitas GD (2010) The 
Endothelium and Its Role in Regulating Vascular Tone. Open Cardiovasc Med J 
4(1):302–312. 
7.  Zhao Y, Vanhoutte PM, Leung SWS (2015) Vascular nitric oxide: Beyond eNOS. J 
Pharmacol Sci 129(2):83–94. 
8.  Mas M (2009) A Close Look at the Endothelium: Its Role in the Regulation of Vasomotor 
Tone. Eur Urol Suppl 8(2):48–57. 
9.  Matthys KE, Bult H (1997) Nitric oxide function in atherosclerosis. Mediators Inflamm 
6(1):3–21. 
10.  Schmitt CA, Heiss EH, Aristei Y, Severin T, Dirsch VM (2009) Norfuraneol 
dephosphorylates eNOS at threonine 495 and enhances eNOS activity in human 
endothelial cells. Cardiovasc Res 81(4):750–757. 
11.  Forstermann U, Munzel T (2006) Endothelial Nitric Oxide Synthase in Vascular Disease: 
From Marvel to Menace. Circulation 113(13):1708–1714. 
12.  Kobayashi J (2015) Nitric oxide and insulin resistance. Immunoendocrinology 2(657):1–9. 
13.  Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G (1987) Endothelium-derived 
relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad 
Sci 84(24):9265–9269. 
41 
14.  Furchgott RF (1988) Vasodilatation: vascular smooth muscle, peptides, autonomic nerves 
and endothelium. Vasodilatation Vasc Smooth Muscle, Pept Auton Nerves Endotelium. 
15.  Schuman EM, Madison D V (1991) A requirement for the intercellular messenger nitric 
oxide in long-term potentiation. Science (80- ) 254(5037):1503–1506. 
16.  Cleeter MWJ, Cooper JM, Darley-Usmar VM, Moncada S, and AHV Schapira (1994) 
Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial 
respiratory chain, by nitric oxide: implications for neurodegenerative diseases. FEBS Lett 
345(1):50–54. 
17.  Bian K, Murad F (2003) Nitric oxide (NO)--biogeneration, regulation, and relevance to 
human diseases. Front Biosci a J virtual Libr 8:264. 
18.  Rapoport RM, Murad F (1983) Agonist-induced endothelium-dependent relaxation in rat 
thoracic aorta may be mediated through cGMP. Circ Res 52(3):352–357. 
19.  Arnold WP, Mittal CK, Katsuki S, Murad F (1977) Nitric oxide activates guanylate 
cyclase and increases guanosine 3’:5’-cyclic monophosphate levels in various tissue 
preparations. Proc Natl Acad Sci U S A 74(8):3203–3207. 
20.  Rathbun BRK, et al. (1997) Inactivation of the Fanconi Anemia Group C Gene Augments 
Interferon-g – Induced Apoptotic Responses in Hematopoietic Cells. Blood 90:974–985. 
21.  Guo T, Wang Q, Pan J, Liu J, Liu D (2019) Epidermal Growth Factor Reverses the 
Inhibitory Effects of the Bisphosphonate, Zoledronic Acid, on Human Oral Keratinocytes 
and Human Vascular Endothelial Cells In Vitro via the Epidermal Growth Factor 
Receptor (EGFR)/Akt/Phosphoinositide 3-Kinase (PI3K) . Med Sci Monit 25:700–710. 
22.  Cooke JP, Losordo DW (2002) Nitric Oxide and Angiogenesis. Circulation 
105(18):2133–2135. 
23.  Michaelis UR, et al. (2013) The Polarity Protein Scrib Is Essential for Directed 
Endothelial Cell Migration. Cell Biol:924–934. 
24.  Goligorsky MS, et al. (2017) Podokinesis in endothelial cell migration: role of nitric 
oxide. Am J Physiol Physiol 274(1):C236–C244. 
25.  Förstermann U, Sessa WC (2012) Nitric oxide synthases: Regulation and function. Eur 
Heart J 33(7):829–837. 
26.  Rafikov R, et al. (2011) eNOS activation and NO function: Structural motifs responsible 
for the posttranslational control of endothelial nitric oxide synthase activity. J Endocrinol 
42 
210(3):271–284. 
27.  Crane BR, et al. (1999) N-terminal domain swapping and metal ion binding in nitric oxide 
synthase dimerization. EMBO J 18(22):6271–6281. 
28.  Alderton WK, Cooper CE, Knowles RG (2001) Nitric oxide synthases: structure, function 
and inhibition. Biochem J 357(3):593–615. 
29.  Gratton JP, et al. (2000) Reconstitution of an endothelial nitric-oxide synthase (eNOS), 
hsp90, and caveolin-1 complex in vitro: Evidence that hsp90 facilitates calmodulin 
stimulated displacement of eNOS from caveolin-1. J Biol Chem. 
doi:10.1074/jbc.M001644200. 
30.  Yokom AL, et al. (2014) Architecture of the nitric-oxide synthase holoenzyme reveals 
large conformational changes and a calmodulin-driven release of the FMN domain. J Biol 
Chem 289(24):16855–16865. 
31.  Ghosh DK, et al. (1999) Inducible nitric oxide synthase: Role of the N-terminal β-hairpin 
hook and pterin-binding segment in dimerization and tetrahydrobiopterin interaction. 
EMBO J 18(22):6260–6270. 
32.  Rodríguez-Crespo I, Gerber NC, Montellano PRO De (1996) Endothelial Nitric-oxide 
Synthase. J Biol Chem 271(19):11462–11467. 
33.  Yetik-Anacak G, Catravas JD (2006) Nitric oxide and the endothelium: History and 
impact on cardiovascular disease. Vascul Pharmacol 45(5):268–276. 
34.  Fulton DJR (2016) Transcriptional and Posttranslational Regulation of eNOS in the 
Endothelium. Adv Pharmacol 77:29–64. 
35.  Klatt P, Schmidt K, Brunner F (1994) Inhibitors of Brain Nitric Oxide Synthase. J Biol 
Chem 269(3):1674–1680. 
36.  Liu Q, Gross SS (1996) Binding sites of nitric oxide synthases. Methods Enzymol 
268:311–324. 
37.  Raman CS, et al. (1998) Crystal structure of constitutive endothelial nitric oxide synthase: 
a paradigm for pterin function involving a novel metal center. Cell 95(7):939–50. 
38.  Zou MH, Shi C, Cohen RA (2002) Oxidation of the zinc-thiolate complex and uncoupling 
of endothelial nitric oxide synthase by peroxynitrite. J Clin Invest 109(6):817–826. 
39.  Udenwobele DI, et al. (2017) Myristoylation: An important protein modification in the 
immune response. Front Immunol 8(JUN):1–16. 
43 
40.  Sakoda T, et al. (1995) Myristoylation of endothelial cell nitric oxide synthase is 
important for extracellular release of nitric oxide. Mol Cell Biochem 152(2):143–148. 
41.  Sessa WC, et al. (1995) The Golgi association of endothelial nitric oxide synthase is 
necessary for the efficient synthesis of nitric oxide. J Biol Chem 270(30):17641–4. 
42.  Liu J, García-Cardeña G, Sessa WC (1995) Biosynthesis and Palmitoylation of 
Endothelial Nitric Oxide Synthase: Mutagenesis of Palmitoylation Sites, Cysteines-15 
and/or -26, Argues against Depalmitoylation-Induced Translocation of the Enzyme. 
Biochemistry 34(38):12333–12340. 
43.  Isoforms NS, et al. (1997) Subunit Interactions of Endothelial Nitric-oxide Synthase. J 
Biol Chem 272(2):1276–1282. 
44.  Marshall C, et al. (1996) Phosphorylation of Endothelial Nitric Oxide Synthase in 
Response to Fluid Shear Stress. Circ Res 79(5):984–991. 
45.  Rafikov R, et al. (2011) eNOS activation and NO function: Structural motifs responsible 
for the posttranslational control of endothelial nitric oxide synthase activity. J Endocrinol 
210(3):271. 
46.  Salerno JC, et al. (2014) Endothelial nitric oxide synthase is regulated by ERK 
phosphorylation at Ser602. Biosci Rep 34(5):e00137. 
47.  McCabe TJ, Fulton D, Roman LJ, Sessa WC (2000) Enhanced electron flux and reduced 
calmodulin dissociation may explain “calcium-independent” eNOS activation by 
phosphorylation. J Biol Chem 275(9):6123–6128. 
48.  Dhananjayan R, Koundinya KSS, Malati T, Kutala VK (2016) Endothelial Dysfunction in 
Type 2 Diabetes Mellitus. Indian J Clin Biochem 31(4):372–379. 
49.  ZHANG W, LIU HT (2002) MAPK signal pathways in the regulation of cell proliferation 
in mammalian cells. Cell Res 12(1):9–18. 
50.  Chrestensen CA, McMurry JL, Salerno JC (2012) Map kinases bind endothelial nitric 
oxide synthase. FEBS Open Bio 2(1):51–55. 
51.  Arroyo JA, Anthony R V., Parker TA, Galan HL (2010) ENOS, NO, and the activation of 
ERK and AKT signaling at mid-gestation and near-term in an ovine model of intrauterine 
growth restriction. Syst Biol Reprod Med 56(1):62–73. 
52.  Feliers D, et al. (2005) VEGF regulation of endothelial nitric oxide synthase in glomerular 
endothelial cells. Kidney Int 68(4):1648–1659. 
44 
53.  Bernier SG, Haldar S, Michel T (2000) Bradykinin-regulated interactions of the mitogen-
activated protein kinase pathway with the endothelial nitric-oxide synthase. JBiolChem 
275(39):30707–30715. 
54.  Park JH, Park M, Byun CJ, Jo I (2012) C-Jun N-terminal kinase 2 phosphorylates 
endothelial nitric oxide synthase at serine 116 and regulates nitric oxide production. 
Biochem Biophys Res Commun 417(1):340–345. 
55.  Michell BJ, et al. (2002) Identification of regulatory sites of phosphorylation of the bovine 
endothelial nitric-oxide synthase at Serine 617 and Serine 635. J Biol Chem 
277(44):42344–42351. 
56.  Dimmeler S, et al. (1999) Activation of nitric oxide synthase in endothelial cells by Akt-
dependent phosphorylation Nature 399: 601–605. Find this Artic online. 
57.  Chen CA, Druhan LJ, Varadharaj S, Chen YR, Zweier JL (2008) Phosphorylation of 
endothelial nitric-oxide synthase regulates superoxide generation from the enzyme. J Biol 
Chem 283(40):27038–27047. 
58.  Meng D, et al. (2009) MEK1 binds directly to βarrestin1, influencing both its 
phosphorylation by ERK and the timing of its isoprenaline-stimulated internalization. J 
Biol Chem 284(17):11425–11435. 
59.  UniProt: a worldwide hub of protein knowledge (2018) Nucleic Acids Res 47(D1):D506–
D515. 
60.  Waterhouse AM, Procter JB, Martin DMA, Clamp M, Barton GJ (2009) Jalview Version 
2-A multiple sequence alignment editor and analysis workbench. Bioinformatics 
25(9):1189–1191. 
61.  Pei J, Kim BH, Grishin N V. (2008) PROMALS3D: A tool for multiple protein sequence 
and structure alignments. Nucleic Acids Res 36(7):2295–2300. 
62.  Yang J, et al. (2014) The I-TASSER suite: Protein structure and function prediction. Nat 
Methods 12(1):7–8. 
63.  Roy A, Kucukural A, Zhang Y (2010) I-TASSER: A unified platform for automated 
protein structure and function prediction. Nat Protoc 5(4):725–738. 
64.  Zhang Y (2008) I-TASSER server for protein 3D structure prediction. BMC 
Bioinformatics 9:1–8. 
65.  The PyMOL Molecular Graphics System Available at: https://pymol.org/2/. 
45 
66.  Zhou HG, Standfuss J, Watson KA, Krasel C A New Dimeric Crystal Form for Arrestin2. 
doi:10.2210/PDB2WTR/PDB. 
67.  Garcin ED, et al. (2004) Structural basis for isozyme-specific regulation of electron 
transfer in nitric-oxide synthase. J Biol Chem 279(36):37918–37927. 
68.  Zhang J, et al. (2001) Crystal structure of the FAD/NADPH-binding domain of rat 
neuronal nitric-oxide synthase. Comparisons with NADPH-cytochrome P450 
oxidoreductase. JBiolChem 276:37506–37513. 
69.  Xia C, Misra I, Iyanaki T, Kim JJK (2009) Regulation of Interdomain Interactions by 
CaM in Inducible Nitric Oxide Synthase. JBiolChem. doi:10.2210/PDB3HR4/PDB. 
70.  Salter M., Knowles R.G. (1998) Assay of NOS Activity by the Measurement of 
Conversion of Oxyhemoglobin to Methemoglobin by NO. In: Titheradge M.A. (eds) 
Nitric Oxide Protocols. Methods in Molecular BiologyTM, vol 100. Humana Press. 
71.  Bren KL, Eisenberg R, Gray HB (2015) Discovery of the magnetic behavior of 
hemoglobin: A beginning of bioinorganic chemistry. Proc Natl Acad Sci 112(43):13123–
13127. 
72.  Salter M, Knowles RG, Moncada S (1991) Widespread tissue distribution, species 
distribution and changes in activity of Ca2+‐dependent and Ca2+‐independent nitric oxide 
synthases. FEBS Press 291(1):145–149. 
73.  Feelisch M, Noack EA (1987) Correlation between nitric oxide formation during 
degradation of organic nitrates and activation of guanylate cyclase. Eur J Pharmacol 
139(1):19–30. 
74.  Chrestensen CA, et al. (2004) MAPKAP Kinase 2 Phosphorylates Tristetraprolin on in 
Vivo Sites Including Ser178, a Site Required for 14-3-3 Binding. J Biol Chem 
279(11):10176–10184. 
75.  Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram 
quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72(1–
2):248–254. 
76.  Sheehan D, O’Sullivan S (2008) Protein electrophoresis. Mol Biomethods Handb Second 
Ed (April):351–363. 
77.  DenHollander N, Befus D (1989) Loss of antigens from immunoblotting membranes. J 
Immunol Methods 122(1):129–135. 
46 
78.  Newman E, et al. (2004) Differential activation of nitric-oxide synthase isozymes by 
calmodulin-troponin C chimeras. J Biol Chem 279(32):33547–33557. 
79.  Chen CA, et al. (2010) S-glutathionylation uncouples eNOS and regulates its cellular and 
vascular function. Nature 468(7327):1115–1120. 
80.  Fulton D, et al. (2004) Insulin resistance does not diminish eNOS expression, 
phosphorylation, or binding to HSP-90. Am J Physiol Circ Physiol 287(6):H2384–H2393. 
81.  Kolluru GK, Siamwala JH, Chatterjee S (2010) eNOS phosphorylation in health and 
disease. Biochimie 92(9):1186–1198. 
82.  Koch SR, Choi H, Mace EH, Stark RJ (2019) Toll-like receptor 3-mediated inflammation 
by p38 is enhanced by endothelial nitric oxide synthase knockdown. Cell Commun Signal 
3:1–13. 
83.  Stephan BCM, et al. (2017) Cardiovascular Disease, the Nitric Oxide Pathway and Risk of 
Cognitive Impairment and Dementia. Curr Cardiol Rep 19(9). doi:10.1007/s11886-017-
0898-y. 
84.  Dhillon AS, Hagan S, Rath O, Kolch W (2007) MAP kinase signalling pathways in 






Table S1:  NOS isolated from diverse species.  
UniProt ID Entry name Organism Length 
Q28969 NOS3_PIG Sus scrofa (Pig) 1205 
P70313 NOS3_MOUSE Mus musculus (Mouse) 1202 
Q62600 NOS3_RAT Rattus norvegicus (Rat) 1202 
P29473 NOS3_BOVIN Bos taurus (Bovine) 1205 
P29474 NOS3_HUMAN Homo sapiens (Human) 1203 
Q9TUX8 NOS3_CANLF 
Canis lupus familiaris (Dog) 
(Canis familiaris) 
1205 
P97270 NOS3_CAVPO Cavia porcellus (Guinea pig) 100 
P79209 NOS3_SHEEP Ovis aries (Sheep) 99 
A0A1D1YKK0 A0A1D1YKK0_9ARAE Anthurium amnicola (tulip)  135 
A0A1D1ZKN4 A0A1D1ZKN4_9ARAE Anthurium amnicola (tulip)  114 
Q80SZ9 Q80SZ9_SPECI 
Citellus citellus (european ground 
squril)  
27 
H9CZP9 H9CZP9_CHICK Gallus gallus (Chicken) 985 
V9ITD3 V9ITD3_CHICK Gallus gallus (Chicken) 1146 
E8Z914 E8Z914_XENTR 
Xenopus tropicalis (Western 
clawed frog) (Silurana tropicalis) 
1177 
H2QVM2 H2QVM2_PANTR Pan troglodytes (Chimpanzee) 1203 
H0WJA4 H0WJA4_OTOGA 
Otolemur garnettii (Small-eared 





























Sarcophilus harrisii (Tasmanian 





















Chelonia mydas (Green sea-turtle) 
(Chelonia agassizi) 
534 
A0A2I0LJM0 A0A2I0LJM0_COLLI Columba livia (Rock dove) 507 
V8NCF8 V8NCF8_OPHHA 
Ophiophagus hannah (King 
cobra) (Naja hannah) 
721 
A0A218UGU3 A0A218UGU3_9PASE 








Eschrichtius robustus (California 




Camelus ferus (Wild bactrian 
camel) (Camelus bactrianus ferus) 
936 
D7RVB4 D7RVB4_RABIT Oryctolagus cuniculus (Rabbit) 1,209 
M3WID9 M3WID9_FELCA 













Xenopus laevis (African clawed 
frog) 
147 
P29475 NOS1_HUMAN Homo sapiens (Human) 1,434 
Q9Z0J4 NOS1_MOUSE Mus musculus (Mouse) 1,429 
P29476 NOS1_RAT Rattus norvegicus (Rat) 1,429 
E1BKI3 E1BKI3_BOVIN Bos taurus (Bovine) 1,325 
J9P395 J9P395_CANLF 
Canis lupus familiaris (Dog) 
(Canis familiaris) 
1,465 
O19132 NOS1_RABIT Oryctolagus cuniculus (Rabbit) 1,435 
F1QVQ6 F1QVQ6_DANRE 
Danio rerio (Zebrafish) 
(Brachydanio rerio) 
1,429 
E1C799 E1C799_CHICK Gallus gallus (Chicken) 1,435 
49 
H0X6T1 H0X6T1_OTOGA 
Otolemur garnettii (Small-eared 












Sarcophilus harrisii (Tasmanian 








Ficedula albicollis (Collared 
flycatcher) (Muscicapa albicollis) 
1,435 
U3IZ92 U3IZ92_ANAPL 




Xenopus tropicalis (Western 
clawed frog) (Silurana tropicalis) 
1,427 
H9GND1 H9GND1_ANOCA 








Mustela putorius furo (European 
domestic ferret) (Mustela furo) 
1,467 
K7FGK0 K7FGK0_PELSI 
Pongo abelii (Sumatran 








Takifugu rubripes (Japanese 
pufferfish) (Fugu rubripes) 
1,418 
I3JWS0 I3JWS0_ORENI 
Oreochromis niloticus (Nile 
tilapia) (Tilapia nilotica) 
1,428 
H2L651 H2L651_ORYLA 
Oryzias latipes (Japanese rice 








Scleropages formosus (Asian 
bonytongue) 
1,420 










C3UNG7 C3UNG7_9CRUS Daphnia magna 1,182 
P35228 NOS2_HUMAN Homo sapiens (Human) 1,153 
P29477 NOS2_MOUSE Mus musculus (Mouse) 1,144 
Q06518 NOS2_RAT Rattus norvegicus (Rat) 1,147 
Q90703 NOS2_CHICK Gallus gallus (Chicken) 1,136 
O54705 NOS2_CAVPO Cavia porcellus (Guinea pig) 1,149 
F1MYR5 F1MYR5_BOVIN Bos taurus (Bovine) 1,156 
Q28314 NOS2_CAPHI Capra hircus (Goat) 110 
Q92037 NOS2_CARAU Carassius auratus (Goldfish) 164 
A0A2D0SXG4 A0A2D0SXG4_ICTPU 
Ictalurus punctatus (Channel 
catfish) (Silurus punctatus) 
1,080 
F7FZ21 F7FZ21_MONDO 








Pongo abelii (Sumatran 




Ficedula albicollis (Collared 
flycatcher) (Muscicapa albicollis) 
1,147 
H0ZEC8 H0ZEC8_TAEGU 








Pelodiscus sinensis (Chinese 
softshell turtle) (Trionyx sinensis) 
1,092 
G3W4E3 G3W4E3_SARHA 
Sarcophilus harrisii (Tasmanian 
devil) (Sarcophilus laniarius) 
1,153 
M3YSE6 M3YSE6_MUSPF 
Mustela putorius furo (European 
domestic ferret) (Mustela furo) 
1,064 
U3J9H8 U3J9H8_ANAPL 




Macaca mulatta (Rhesus 
macaque) 
1,112 
A0A287BRU8 A0A287BRU8_PIG Sus scrofa (Pig) 1,195 
G3UTC3 G3UTC3_MELGA 




Xenopus tropicalis (Western 
clawed frog) (Silurana tropicalis) 
1,109 
H9GMP6 H9GMP6_ANOCA 









Mesocricetus auratus (Golden 
hamster) 
1,150 






Oncorhynchus mykiss (Rainbow 
trout) (Salmo gairdneri) 
1,083 
A0A1S3T1I3 A0A1S3T1I3_SALSA Salmo salar (Atlantic salmon) 1,083 
A0A1X0QFB2 A0A1X0QFB2_9MICR Hepatospora eriocheir 356 
T2MFR4 T2MFR4_HYDVU 




Nematostella vectensis (Starlet 
sea anemone) 
256 
Q670V8 Q670V8_PODCA Podocoryna carnea (Hydrozoan) 333 
 
 
